Technology

Alphabody™ platform - Unique drug development engine

The Alphabody™ platform is based on the vision of Complix´s founders that an ideal therapeutic protein scaffold should contain a number of key properties in terms of target selectivity, stability, pharmacokinetics, safety, and potential modes of administration. Usually such properties are not displayed, at least not in a combined way, by monoclonal antibodies, or any other of the currently available, antibody-derived, or alternative scaffold based therapeutic proteins.

By integrating expert knowledge on structural elements of naturally occurring human proteins with computer-aided rational design concepts, the scientific founders of Complix have created a novel protein scaffold that harbors many of the desired characteristics of an optimal therapeutic molecule: the “Alphabody™”.

Strong IP position – independent of antibody IP

Through the filing of several broad patent applications Complix has established a strong intellectual property position on the Alphabody™ technology. Because the Alphabody™ scaffold structure is totally unrelated to immunoglobulins, Alphabodies™ are independent of antibody based patent claims.